175 related articles for article (PubMed ID: 9833984)
1. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123.
de Lange EC; de Bock G; Schinkel AH; de Boer AG; Breimer DD
Pharm Res; 1998 Nov; 15(11):1657-65. PubMed ID: 9833984
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
de Lange EC; Marchand S; van den Berg D; van der Sandt IC; de Boer AG; Delon A; Bouquet S; Couet W
Eur J Pharm Sci; 2000 Dec; 12(2):85-93. PubMed ID: 11102735
[TBL] [Abstract][Full Text] [Related]
3. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.
Xie R; Hammarlund-Udenaes M; de Boer AG; de Lange EC
Br J Pharmacol; 1999 Oct; 128(3):563-8. PubMed ID: 10516633
[TBL] [Abstract][Full Text] [Related]
4. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants.
Cox DS; Scott KR; Gao H; Raje S; Eddington ND
J Pharm Sci; 2001 Oct; 90(10):1540-52. PubMed ID: 11745712
[TBL] [Abstract][Full Text] [Related]
5. Transfer of rhodamine-123 into the brain and cerebrospinal fluid of fetal, neonatal and adult rats.
Koehn LM; Dziegielewska KM; Habgood MD; Huang Y; Saunders NR
Fluids Barriers CNS; 2021 Feb; 18(1):6. PubMed ID: 33557872
[TBL] [Abstract][Full Text] [Related]
6. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier.
Gaillard PJ; van der Sandt IC; Voorwinden LH; Vu D; Nielsen JL; de Boer AG; Breimer DD
Pharm Res; 2000 Oct; 17(10):1198-205. PubMed ID: 11145224
[TBL] [Abstract][Full Text] [Related]
7. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.
van der Sandt IC; Smolders R; Nabulsi L; Zuideveld KP; de Boer AG; Breimer DD
Eur J Pharm Sci; 2001 Aug; 14(1):81-6. PubMed ID: 11457654
[TBL] [Abstract][Full Text] [Related]
8. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
9. Microdialysis for pharmacokinetic analysis of drug transport to the brain.
de Lange EC ; de Boer BA ; Breimer DD
Adv Drug Deliv Rev; 1999 Apr; 36(2-3):211-227. PubMed ID: 10837717
[TBL] [Abstract][Full Text] [Related]
10. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.
Vautier S; Lacomblez L; Chacun H; Picard V; Gimenez F; Farinotti R; Fernandez C
Eur J Pharm Sci; 2006 Feb; 27(2-3):167-74. PubMed ID: 16263252
[TBL] [Abstract][Full Text] [Related]
11. The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.
Mairinger S; Bankstahl JP; Kuntner C; Römermann K; Bankstahl M; Wanek T; Stanek J; Löscher W; Müller M; Erker T; Langer O
Epilepsy Res; 2012 Jun; 100(1-2):93-103. PubMed ID: 22342565
[TBL] [Abstract][Full Text] [Related]
12. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1192-9. PubMed ID: 12948017
[TBL] [Abstract][Full Text] [Related]
13. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
[TBL] [Abstract][Full Text] [Related]
14. Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats.
Wang Q; Yang H; Miller DW; Elmquist WF
Biochem Biophys Res Commun; 1995 Jun; 211(3):719-26. PubMed ID: 7598699
[TBL] [Abstract][Full Text] [Related]
15. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
[TBL] [Abstract][Full Text] [Related]
16. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
17. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone.
Karssen AM; Meijer OC; van der Sandt IC; De Boer AG; De Lange EC; De Kloet ER
J Endocrinol; 2002 Oct; 175(1):251-60. PubMed ID: 12379510
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
20. Carbamazepine is not a substrate for P-glycoprotein.
Owen A; Pirmohamed M; Tettey JN; Morgan P; Chadwick D; Park BK
Br J Clin Pharmacol; 2001 Apr; 51(4):345-9. PubMed ID: 11318771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
